Schonfeld Strategic Advisors LLC - ULTRAGENYX PHARMACEUTICAL IN ownership

ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 232 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q4 2021. The put-call ratio across all filers is 8.37 and the average weighting 0.1%.

Quarter-by-quarter ownership
Schonfeld Strategic Advisors LLC ownership history of ULTRAGENYX PHARMACEUTICAL IN
ValueSharesWeighting
Q1 2023$780,906
-38.7%
19,474
-8.8%
0.01%
-41.7%
Q2 2022$1,273,000
+46.0%
21,348
+120.8%
0.01%
+33.3%
Q3 2021$872,000
+294.6%
9,670
+317.4%
0.01%
+350.0%
Q2 2021$221,000
-20.8%
2,317
-64.6%
0.00%
-71.4%
Q4 2019$279,000
-68.4%
6,545
-52.9%
0.01%
-77.4%
Q2 2019$883,000
-28.0%
13,900
-21.5%
0.03%
-27.9%
Q1 2019$1,227,000
-16.0%
17,700
-47.3%
0.04%
-23.2%
Q4 2018$1,460,000
-47.2%
33,607
-7.2%
0.06%
-54.5%
Q3 2018$2,763,000
+35.2%
36,200
-9.6%
0.12%
-19.6%
Q1 2018$2,043,000
+592.5%
40,050
+823.4%
0.15%
+410.0%
Q1 2017$295,0004,3370.03%
Other shareholders
ULTRAGENYX PHARMACEUTICAL IN shareholders Q4 2021
NameSharesValueWeighting ↓
EcoR1 Capital, LLC 519,119$40,605,0003.00%
First Light Asset Management, LLC 236,958$18,535,0002.16%
SECTOR GAMMA AS 108,734$8,505,0001.76%
Rock Springs Capital Management LP 646,841$50,596,0001.39%
Capital Impact Advisors, LLC 30,582$2,392,0000.80%
Atika Capital Management LLC 79,000$6,180,0000.80%
FEDERATED HERMES, INC. 4,080,359$319,166,0000.79%
Rhenman & Partners Asset Management AB 61,500$4,811,0000.52%
Ikarian Capital, LLC 73,500$5,749,0000.46%
Capital International, Inc./CA/ 477,858$37,378,0000.46%
View complete list of ULTRAGENYX PHARMACEUTICAL IN shareholders